Genetic Information

Gene & Transcript Details

Gene
PTPN11
Transcript
NM_001330437.1 MANE Select
Total Exons
Reference Sequence
NC_000012.11
Alternative Transcripts
IDStatusDetails
NM_001330437.2 Alternative 6085 nt | 166–1959
NM_001330437.1 Alternative 6151 nt | 215–2008

Variant Details

HGVS Notation
NM_001330437.1:c.1052G>A
Protein Change
R351Q
Location
Exon 9 (Exon 9 of )
9
5'Exon Structure3'
Functional Consequence
Loss of Function
Alternate Identifiers

Clinical & Population Data

Population Frequency

gnomAD
Global Frequency
0.0426 in 100,000
Extremely Rare
ACMG Criteria Applied PM2
This variant is absent or extremely rare in population databases (PM2 criteria applies).

ClinVar

Open
Classification
Uncertain Significance (VUS)
3 publications
Publications List
PMID: 15385933

Variant summary: PTPN11 c.1052G>A (p.Arg351Gln) results in a conservative amino acid change located in the PTP type protein phosphatase domain (IPR000242) of the encoded protein sequence. Three of five in-silico tools predict a benign effect of the variant on protein function. The variant allele was found at a frequency of 0.00043 in 251446 control chromosomes. The observed variant frequency is approximately 6.81 fold of the estimated maximal expected allele frequency for a pathogenic variant in PTPN11 causing Noonan Syndrome phenotype (6.3e-05), strongly suggesting that the variant is benign. To our knowledge, no occurrence of c.1052G>A in individuals affected with Noonan Syndrome and no experimental evidence demonstrating its impact on protein function have been reported. Two clinical diagnostic laboratories and an expert panel (ClinGen RASopathy Variant Curation Expert Panel) have submitted clinical-significance assessments for this variant to ClinVar after 2014 without evidence for independent evaluation (benign/likely benign, n=2; VUS, n=1). Based on the evidence outlined above, the variant was classified as benign.

Clinical Statement

"This variant has been reported in ClinVar as Benign (5 clinical laboratories) and as Uncertain significance (1 clinical laboratories) and as Likely benign (1 clinical laboratories) and as Benign by ClinGen RASopathy Variant Curation Expert Panel expert panel."

COSMIC Somatic Evidence

Open
COSMIC ID
COSM6914105
Recurrence
6 occurrences
PM1 Criteria
Not Applied
COSMIC Database Preview
COSMIC Preview
Accessing full COSMIC database details requires institutional login or subscription.

Functional Impact & Domains

Functional Domain

Hotspot Status
Not a hotspot
Domain Summary
This variant is not located in a mutational hotspot or critical domain.
Related Variants in This Domain
No evidence of other pathogenic variants at this position in gene PTPN11.

Functional Studies & Therapeutic Relevance

Functional Summary

Error in OpenAI Consolidation. OncoKB: PTPN11R351QPTPN11R351QSomaticNCBI Gene:5781|Show additional gene information Variant OverviewPTPN11, a protein tyrosine phosphatase, is altered in various solid and hematologic malignancies.There is no available functional data about the PTPN11 R351Q mutation (last reviewed on 04/06/2017), and therefore its biological significance is unknown. JAX-CKB: No results found

Database Previews
OncoKB
OncoKB Preview
JAX-CKB
JAX-CKB Preview

Click on previews to view full database entries. External databases may require institutional access.

Computational Analysis

Pathogenicity Predictions

SpliceAI
Predictor Consensus
Mixed/VUS
PP3 Applied
No
REVEL Score
0.0
Threshold: ≥0.75 = PP3 applied

SpliceAI Scores

Window: ±500bp
Effect Type Score Position
- Acceptor Loss (AL) 0.0 -140 bp
- Donor Loss (DL) 0.0 40 bp
+ Acceptor Gain (AG) 0.0 3 bp
+ Donor Gain (DG) 0.0 -41 bp
High impact (≥0.5) Medium impact (0.2-0.49) Low impact (<0.2)

VCEP Guidelines

Applied ACMG/AMP Criteria (VCEP Specific)

Filter Criteria:
PM2

PM2 (Unknown (Pre-LLM))

From pre-LLM assessment (LLM Failed)

BP4

BP4 (Unknown (Pre-LLM))

From pre-LLM assessment (LLM Failed)